YS Biopharma SPAC Presentation Deck
September 2022, 37 slides
  1. YS Biopharma
  2. SPAC Presentation Decks
corporate presentation summit | YS Biopharma
disclaimer | YS Biopharma
| YS Biopharma
| YS Biopharma
risk factors | YS Biopharma
risk factors continued | YS Biopharma
risk factors continued | YS Biopharma
risk factors continued | YS Biopharma
risk factors continued | YS Biopharma
risk factors continued | YS Biopharma
risk factors continued | YS Biopharma
presenters summit | YS Biopharma
agenda transaction structure overview company overview | YS Biopharma
transaction structure overview a | YS Biopharma
transaction summary | YS Biopharma
valuation analysis | YS Biopharma
bonus share structure for non redeeming public shareholders and investors | YS Biopharma
transaction structure | YS Biopharma
corporate structure post business combination listing | YS Biopharma
overview | YS Biopharma
vision of to become a global leader in transformative vaccines and therapeutic | YS Biopharma
at a glance robust revenue growth of rabies vaccine driven by rising price and market share expansion which was administered million doses with proven efficacy and safety pika covid vaccine potential to become a prophylactic and therapeutic vaccine against multiple virus variants pika rabies vaccine a who designated innovative vaccine featuring accelerated regimen and superior efficacy and potential to elevate the standard of care strong capabilities underpinned by innovative pika technology platform established infrastructure and in vaccine and production new product launch and commercialization | YS Biopharma
at a glance integrated platform from discovery to commercialization | YS Biopharma
diverse product pipeline driving near term and long term growth patrons | YS Biopharma
financing milestones backed by international leading investors us rowen | YS Biopharma
innovative pika technology platform strong intellectual property position with patents granted by countries pik a | YS Biopharma
leading vaccine platform with years of tracking record a a | YS Biopharma
seasoned management team with global vision local execution is | YS Biopharma
distinguished board of directors with global vision industry leaderships | YS Biopharma
global and china vaccine market driven by product launches and market expansion | YS Biopharma
china human rabies vaccine market robust sustainable demand and expansion | YS Biopharma
marketed rabies vaccine offers significant revenue commercialization potential | YS Biopharma
financial overview achieved revenues increase profitability improvement | YS Biopharma
financial overview achieved revenues increase profitability improvement | YS Biopharma
our future strategies to drive business growth and value creation | YS Biopharma
upcoming milestones developments over the next months | YS Biopharma
thank you a | YS Biopharma
See More
YS Biopharma
SPAC Presentation Decks
Explore Topics
Biopharma
Vaccine
Manufacturing
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights